- Home
- CVKD vs RVPH Comparison
CVKD vs RVPH Comparison
Compare CVKD & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- RVPH
- Stock Information
- Founded
- CVKD 2022
- RVPH 2006
- Country
- CVKD United States
- RVPH United States
- Employees
- CVKD N/A
- RVPH N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- RVPH Health Care
- Exchange
- CVKD Nasdaq
- RVPH Nasdaq
- Market Cap
- CVKD 29.5M
- RVPH 32.8M
- IPO Year
- CVKD 2023
- RVPH N/A
- Fundamental
- Price
- CVKD $12.79
- RVPH $0.40
- Analyst Decision
- CVKD Strong Buy
- RVPH Strong Buy
- Analyst Count
- CVKD 1
- RVPH 5
- Target Price
- CVKD $32.00
- RVPH $9.00
- AVG Volume (30 Days)
- CVKD 35.0K
- RVPH 3.1M
- Earning Date
- CVKD 08-06-2025
- RVPH 08-13-2025
- Dividend Yield
- CVKD N/A
- RVPH N/A
- EPS Growth
- CVKD N/A
- RVPH N/A
- EPS
- CVKD N/A
- RVPH N/A
- Revenue
- CVKD N/A
- RVPH N/A
- Revenue This Year
- CVKD N/A
- RVPH N/A
- Revenue Next Year
- CVKD N/A
- RVPH N/A
- P/E Ratio
- CVKD N/A
- RVPH N/A
- Revenue Growth
- CVKD N/A
- RVPH N/A
- 52 Week Low
- CVKD $5.70
- RVPH $0.30
- 52 Week High
- CVKD $22.90
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- CVKD 49.98
- RVPH 33.44
- Support Level
- CVKD $11.00
- RVPH $0.35
- Resistance Level
- CVKD $13.56
- RVPH $0.83
- Average True Range (ATR)
- CVKD 1.15
- RVPH 0.06
- MACD
- CVKD 0.25
- RVPH -0.01
- Stochastic Oscillator
- CVKD 80.97
- RVPH 17.36
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.